Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Med Hypotheses. 2013 Sep;81(3):439-42. doi: 10.1016/j.mehy.2013.06.004. Epub 2013 Jul 4.

LGR5 is a biomarker for stratification of HER-2 positive breast cancer patients and personalized treatment.

Author information

  • 1Department of Anesthesiology, Second Xiangya Hospital, Central South University, Anesthesiology Research Institute, Central South University, Changsha, Hunan, China.

Abstract

VEGFR and HER2 are both important transmembrane proteins associated with several types of cancer. Overexpression of these 2 proteins had long been thought to contribute to cancer progression and poor outcomes, thus, therapies targeting HER-2 and VEGFA signaling pathways have been applied in recent years. Herceptin is a HER-2 targeted antibody that being widely used for the management of HER-2 positive breast cancer, which demonstrate significant benefits in both the metastatic and adjuvant settings. However, acquired resistance develops in most treated patients despite treatment in as early as 10 months. Identification of subpopulations best suited for and most likely to respond to Herceptin is of utmost importance. We analyzed the signaling pathways of HER-2 and found that HER-2 shares a very similar downstream network with VEGFA, while LGR5 lies in the upstream of VEGFA and could promotes its expression through CTNNB1. This discovery suggests that the LGR5 directed VEGFA overexpression may activate downstream signals of HER-2 despite Herceptin treatment. Here, we hypothesized that in LGR5 overexpressing breast cancer cases, activation of VEGFA-VRGFR bypass may account for the resistance to HER-2 directed therapies. Concurrent inhibition of VEGFR might enhance Herceptin sensitivity and moreover reverse the resistant phenotype in HER-2 positive breast cancer. Thus, we proposed alternate regimens to increase the efficacy of Herceptin-based therapy. Nevertheless, wet lab experiments and clinical trials are still required.

Copyright © 2013 Elsevier Ltd. All rights reserved.

KEYWORDS:

AKT; CTNNB1; HER-2; IgG1; LGR5; MAPK; P27; PI3K; PTEN; RER; VEGFA; VEGFR; catenin (cadherin-associated protein), beta 1; cyclin-dependent kinase inhibitor 1B (p27, Kip1); immunoglobulin G 1; leucine-rich repeat containing G protein-coupled receptor 5; mitogen-activated protein kinase; phosphatase and tensin homolog; phosphoinositide-3-kinase; rough endoplasmic reticulum; v-akt murine thymoma viral oncogene; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2; vascular endothelial growth factor A; vascular endothelial growth factor receptor

PMID:
23830593
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk